Purpose: Previous red blood cell (RBC) membrane-coated nanoparticles have all been spherical, missing the physical shape component of biomimicry. Particle shape is a critical design parameter affecting biodistribution, macrophage evasion, and targeted interactions. A platform combining physical biomimicry (anisotropic shape) with chemical biomimicry (RBC membrane coating) could improve circulation time and detoxification efficacy.
Hypothesis: If biodegradable polymeric nanoparticles are fabricated into anisotropic shapes and coated with RBC membranes, then the anisotropic shape and membrane coating will synergize to reduce macrophage uptake, prolong blood circulation, improve biodistribution, and enhance detoxification of bacterial alpha toxin in vitro and in vivo.
Aims: Fabricate spherical, prolate ellipsoidal, and oblate ellipsoidal PLGA nanoparticles and coat them with RBC membrane-derived vesicles. - Characterize particle size, zeta potential, membrane coating, and CD47 “marker of self” presentation. - Quantify macrophage uptake in vitro and systemic circulation/biodistribution in vivo. - Evaluate detoxification capability in vitro and survival benefit in a murine alpha toxin/sepsis model.
Delivery system:
Component: Core material; Details: Poly(lactic-co-glycolic acid) (PLGA), 50:50 lactide:glycolide, 38–54 kDa
Component: Particle shapes; Details: Spherical; prolate ellipsoidal (1D stretch, 1.5- or 2-fold); oblate ellipsoidal (2D stretch, 1.5-fold)
Component: Fabrication; Details: Single emulsion for spherical; thin-film stretching for anisotropic shapes
Component: Surface coating; Details: Mouse RBC membrane-derived vesicles; sonication-assisted coating
Component: Key surface protein; Details: CD47 (marker of self) retained on coated particles
Component: Payload; Details: DiD or near-IR hydrophobic dye for imaging; no therapeutic gene/drug payload
Component: Therapeutic mechanism; Details: Membrane-coated particles act as decoys to absorb alpha toxin
Component: Size; Details: Anisotropic particles ~240 nm; coating increased diameter by ~17.2 nm
Component: Zeta potential; Details: Uncoated spherical ~ -35.9 mV; coated ~ -28.3 mV; RBC vesicles ~ -27.2 mV
Component: Targeting ligand; Details: None in this study
Approach: In vitro model: RAW 264.7 murine macrophages for phagocytic uptake; mouse RBCs for hemolysis/toxin neutralization. - In vivo model: C57BL/6J mice; pharmacokinetics/biodistribution with n = 3 mice per group; survival study with n = 6 mice per group. - Doses: Particles injected intravenously via retroorbital route; for detoxification, lethal alpha toxin 2.5 µg/mouse followed 2 min later by 3 mg particles/mouse. - Controls: Uncoated spherical, coated spherical, coated prolate ellipsoidal, coated oblate ellipsoidal, and no-treatment groups. - Disease context: Sepsis/alpha toxin exposure; no tumor or gene therapy model.
Key methods: Particle characterization: Transmission electron microscopy (TEM), dynamic light scattering (DLS), zeta potential, anti-CD47 fluorescence. - Macrophage uptake: Flow cytometry and confocal microscopy. - In vivo pharmacokinetics: Blood sampling at 15, 30, 45 min, 2, 4, 24 h; single-phase exponential decay fit for half-life. - Biodistribution: Organ fluorescence imaging (spleen, kidney, liver, lung, heart) at 4, 24, 72 h. - Detoxification: In vitro hemolysis assay (absorbance at 540 nm); in vivo survival tracked by log-rank (Mantel-Cox) test.
Key results: Macrophage uptake: RBC membrane coating reduced uptake by 30–50%; anisotropic shape reduced uptake by 30–40%; combined coating + anisotropy reduced uptake by 50–70% versus spherical uncoated particles at 4 h. - Blood half-life: Uncoated spherical = 24.6 min; coated spherical = 64.8 min; coated prolate ellipsoidal = 171.6 min; coated oblate ellipsoidal = 82.0 min. Coated prolate particles achieved ~6-fold longer half-life than uncoated spherical particles. - Detoxification in vitro: Anisotropic RBC-coated particles absorbed significantly more alpha toxin than spherical coated particles; reduced hemolysis scaled with increased surface area-to-volume ratio. - In vivo survival: Untreated mice had median survival of 2.75 h; uncoated and spherical coated particles showed no significant survival improvement. Anisotropic coated particles significantly improved survival: ~50% of prolate-treated and ~33% of oblate-treated mice were healthy at 1 week. Prolate coated vs spherical coated: P = 0.0481; anisotropic coated vs uncoated: P = 0.0105 (prolate) and P = 0.0169 (oblate).
Interpretation: The authors claim that combining physical (anisotropic shape) and chemical (RBC membrane coating) biomimicry synergizes to enhance nanoparticle circulation, reduce macrophage clearance, and improve detoxification. They propose anisotropic RBC membrane-coated nanoparticles as a promising modular platform for detoxification agents, drug delivery vehicles, and biological sensors.
Limitations: No targeting ligand was incorporated; targeting is suggested as a future direction. - No therapeutic drug or gene payload was delivered; the therapeutic effect relies on toxin sequestration by the membrane. - Only a murine alpha toxin/sepsis model was used; no large-animal or human validation. - Pharmacokinetic/biodistribution studies used n = 3 mice per group; survival studies used n = 6 mice per group. - The effect of particle curvature on membrane fluidity and stability was not investigated. - Oblate ellipsoidal particles performed well in vitro but less well than prolate particles in vivo; the authors hypothesize hydrodynamic differences but do not fully resolve the mechanism. - Long-term safety, immunogenicity, and repeated-dose toxicity were not assessed. - No in vivo tumor or gene delivery efficacy data are provided.
